Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesVerrica Pharmaceuticals Inc

Verrica Pharmaceuticals Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
3.5128 USD 0.32 ( 10.12%)
Last update at 2026-11-09T15:24:00Z
VOLUME
5009
Market Cap
357.18M

Momentum Score

…

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
3.25
Low
3.51
High
52 Week Price Range
2.86
Low
11.41
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Verrica Pharmaceuticals develops and commercializes prescription topical medicines for common dermatologic conditions such as warts and viral skin infections. Long-term growth could be supported by expanded indications for its topical platform, licensing or partnership deals and broader market demand for dermatology treatments, which may appeal to investors seeking specialty dermatology exposure.
Key risks include regulatory and clinical outcome uncertainty, reliance on a limited product portfolio, potential need for additional financing and competition from established or generic therapies.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
3.19
Dividend Yield
-
Revenue TTM
8.91M
Revenue Per Share
0.19
Gross Profit TTM
8.31M
Debt / Equity
2.30
ROE
-243.35%
Net Debt
-24.04M
ROCE
-32.98%
Diluted EPS TTM
-1.75

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -24.49M -35.08M -42.69M -28.21M -20.65M
Net income -27.68M -38.90M -45.50M -27.95M -20.65M
Selling general administrative 17.41M 26.98M 24.51M 14.64M 9.05M
Gross profit 8.31M 12.00M - - 0.00M
Reconciled depreciation 0.72M 0.47M 0.23M 0.26M 0.02M
Ebit -21.30M -30.91M -40.18M -30.34M -20.67M
Ebitda -20.88M -30.79M -39.66M -30.08M -20.65M
Depreciation and amortization 0.42M 0.12M 0.52M 0.26M 0.02M
Non operating income net other -1.02M 0.12M 0.52M 1.87M 1.23M
Operating income -21.30M -30.91M -40.18M -30.08M -21.88M
Other operating expenses 30.33M 42.91M 40.18M 30.08M 21.88M
Interest expense 2.17M 4.29M 3.03M 0.00M 0.00M
Interest income 0.48M 0.12M 0.52M 1.88M 1.23M
Net interest income -1.70M -4.17M -2.51M 1.88M 1.23M
Income tax expense 3.19M 3.82M 2.80M -0.26M 1.23M
Total revenue 9.03M 12.00M 0.00M 0.00M 0.00M
Total operating expenses 29.60M 42.91M 40.18M 30.08M 21.88M
Cost of revenue 0.72M - - - 0.00M
Total other income expense net -3.19M -4.17M -2.51M 1.87M -0.00M
Net income from continuing ops -24.49M -35.08M -42.69M -28.21M -20.65M
Net income applicable to common shares -24.49M -35.08M -42.69M -28.21M -20.65M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 81.60M 44.72M 80.12M 74.15M 68.42M
Other current assets 2.54M 4.84M 3.97M 2.18M 2.97M
Total liab 61.83M 4.69M 47.52M 41.17M 3.41M
Total stockholder equity 19.76M 40.03M 32.60M 32.99M 65.02M
Deferred long term liab - - - 0.10M -
Other current liab 13.86M 2.65M 3.27M 3.11M 2.04M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -230.45M -163.45M -138.97M -103.89M -61.19M
Other liab - - - 5.85M -
Other assets 0.00M 0.28M 0.29M 1.57M 1.24M
Cash 69.55M 34.27M 15.75M 10.69M 9.24M
Total current liabilities 17.02M 3.46M 46.05M 39.48M 3.35M
Current deferred revenue - - - 0.50M -
Net debt -24.04M -32.75M 27.66M 24.63M -9.05M
Short term debt 0.70M 0.30M 41.94M 35.51M 0.13M
Short long term debt - - 41.69M 35.31M -
Short long term debt total 45.51M 1.53M 43.41M 35.31M 0.19M
Other stockholder equity 250.21M 203.48M 171.60M 136.87M 126.18M
Property plant equipment - 3.89M 3.89M 4.94M 2.20M
Total current assets 77.53M 39.12M 74.33M 65.47M 64.98M
Net tangible assets - 40.03M 32.60M 32.99M 65.02M
Short term investments - 0.00M 54.60M 54.78M 52.78M
Net receivables 4.42M 0.49M - - -
Long term debt 42.87M - - 35.31M -
Inventory 1.02M -0.49M - - -
Accounts payable 2.46M 0.51M 0.84M 0.35M 1.19M
Accumulated other comprehensive income 0.00M - -0.03M 0.00M 0.02M
Common stock total equity - 0.00M 0.00M 0.00M 0.00M
Retained earnings total equity - -163.45M -138.97M -103.89M -61.19M
Non currrent assets other 0.45M 0.28M 0.29M 3.75M 1.24M
Non current assets total 4.07M 5.61M 5.80M 8.68M 3.44M
Capital lease obligations 2.64M 1.53M 1.72M 1.89M 0.19M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 54.52M 0.09M -1.89M 27.86M -79.12M
Change to liabilities -0.59M 0.20M -0.34M 0.01M 1.86M
Total cashflows from investing activities 54.04M -1.00M -3.58M 25.95M -79.89M
Net borrowings -43.77M 4.97M 34.46M 34.46M 34.46M
Total cash from financing activities -16.87M 33.65M 35.23M 0.42M 99.38M
Change to operating activities -0.97M -0.53M 1.97M -1.95M 0.14M
Net income -24.49M -35.08M -42.69M -28.21M -20.65M
Change in cash 18.52M 5.07M 1.45M -1.03M 1.61M
Begin period cash flow 15.75M 10.69M 9.24M 10.27M 8.66M
End period cash flow 34.27M 15.75M 10.69M 9.24M 10.27M
Total cash from operating activities -18.65M -27.58M -30.21M -27.41M -17.87M
Issuance of capital stock 26.90M 28.12M - 0.00M 107.25M
Depreciation 0.72M 0.47M 0.23M 0.26M 0.02M
Other cashflows from investing activities -0.18M -0.20M -0.22M -1.22M -0.50M
Change to account receivables -0.49M -0.49M 0.41M -0.49M -
Sale purchase of stock 26.90M 28.68M 0.45M 0.42M 78.38M
Other cashflows from financing activities -0.02M 5.53M 35.23M 0.42M 13.13M
Change to netincome 6.80M 7.50M 10.62M 3.33M 2.25M
Capital expenditures 0.30M 0.88M 1.47M 0.68M 0.77M
Cash flows other operating -0.94M -0.51M 1.71M -1.55M -0.92M
Cash and cash equivalents changes 18.52M 5.07M 1.45M -1.03M 1.61M
Change in working capital -1.80M -0.54M 1.64M -1.73M 0.94M
Stock based compensation 4.99M 6.05M 9.82M 3.33M 2.25M
Other non cash items 1.93M 1.44M 0.94M -1.06M -0.43M
Free cash flow -18.95M -28.46M -31.68M -28.09M -18.65M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
VRCA
Verrica Pharmaceuticals Inc		 0.32
10.12%		 3.51 - - 56.87 14.83 52.51 -4.33
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 0.34
0.06%		 547.43 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 8.76
0.97%		 913.11 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Verrica Pharmaceuticals Inc

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

44 West Gay Street, West Chester, PA, United States, 19380

484 453 3300

https://www.verrica.com

100

Name Title Year Born
Mr. Ted White Pres, CEO & Director 1965
Mr. Joe Bonaccorso Chief Commercial Officer 1964
Dr. Gary Goldenberg M.D. Chief Medical Officer 1977
Mr. P. Terence Kohler Chief Financial Officer NA
Mr. Christopher G. Hayes Chief Legal Officer, Sec., Chief Compliance Officer & Gen. Counsel 1964
Mr. Eugene Scavola Exec. VP of Technical Operations NA
Dr. Bradley J. Catalone MBA, Ph.D. Head of Drug Devel. NA
Mr. Ted White President, CEO & Director 1965
Mr. Christopher G. Hayes Chief Legal Officer, Secretary, Chief Compliance Officer & General Counsel 1964
Mr. Eugene Scavola Executive Vice President of Technical Operations NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.96
+38.15%
MOON
CAD 4.83
+9.64%
PDN
CAD 8.13
+7.68%
BDT
CAD 72.82
+6.65%
HG
CAD 4.28
+6.20%
CSU
CAD 3300.00
-6.42%
CURA
CAD 12.68
-4.16%
DIV
CAD 3.93
-3.44%
SOIL
CAD 7.18
-3.10%
OBE
CAD 13.31
-2.92%

Equity Sectors*

  • Basic Materials

    +3.19%

  • Communication Services

    -0.04%

  • Consumer Cyclical

    +0.27%

  • Consumer Defensive

    -0.21%

  • Energy

    +1.16%

  • Financial Services

    +0.81%

  • Healthcare

    +0.03%

  • Industrials

    +1.64%

  • Real Estate

    +0.06%

  • Technology

    +0.38%

  • Utilities

    +0.68%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…